Correction of hyperphosphatemia in cats with chronic kidney disease of the third stage

Chronic kidney disease is one of the most common geriatric diseases. According to world data, every 3 cats over the age of 10 have chronic kidney disease. Chronic kidney disease is characterized by impaired excreto ry, biosynthetic, and regulatory functions. During the progression of the disease, there is a loss of functional tissue and subsequent replacement with connective tissue. In our work, we studied cats and kittens weighing between 2.3 and 6.0 kg, aged between 8 and 14 years (n=60). All patients were diagnosed with the third stage of chronic kidney disease according to the IRIS classification. Hematological studies were conducted at the Veterinary Hospital of the Vavilov University, and blood samples were collected on days 1, 30, and 60. During the study, all patients received the BestDinerRenal diet and symptomatic treatment. All cats were divided into 3 groups (n=20). Cats of the first group were given the drugs Sevelamer (Renagel) at a dose of 100 mg/kg/day, the duration of the reception was 60 days. Cats of the second group received as a phosphate binder Lanthanum Carbonate (Fosrenol) 100 mg/kg/day, the duration of the course was 60 days. Cats of the 3rd group were the control group, and did not receive phosphorous-binding drugs, but only a therapeutic diet. As the disease progresses, there is a loss of functional tissue and subsequent replacement with connective tissue. At the moment, there is no mechanism to help restore the volume of functional tissue, and all efforts of veterinary specialists are aimed at reducing the rate of progression of the development of renal failure. One of the factors that provoke the progression of renal failure is hyperphosphatemia. During our study, for all groups, there was no deterioration in the general condition and death of animals.

1. Brown, S.A. Effect of intestinal phosphorus binding on serum phosphorus and parathyroid hormone concentrations in cats with reduced renal function / Brown S.A., Rickertsens M., Sheldon S. // Trainee J ApplResVetMed 2008; 6: 155–60.

2. Dibartholomew, S. Phosphorus disorders: hypophosphatemia and hyperphosphatemia. In: Dibartola SP, ed. Fluid, Electrolyte, and Acid-Base Disorders in Small Animal Practice / Dibartola S.., Willard M.D. // 3rd ed. Missouri: Elsevier. 2006: 195-209.

3. Persey, V. Lanthanum: a safe phosphate binder / Persey V., Behets G.J., Bervoets A.R., De Bro M.E., D'haze K. // Dial Semina 2006; 19: 195-99.

4. Ross, S.D. Clinical evaluation of modification diet for the treatment of spontaneous chronic kidney disease in cats / Ross S.D., Osborn K.A., Kirk K.A., Lowry S.R., Koehler L.A., Polzin D.J. // J AmVetMedAssoc 2006; 229:949-57.

5. Shropp, D.M. Phosphorus and phosphate metabolism in veterinary patients / Shropp D.M. // J VetEmergCritCare 2006; 17:127-34.

6. Murer, H. Transcellular transport of calcium and inorganic phosphate in the small intestinal epithelium. Am J PhysiolGastrointest / Murer H. Hildmann B. //Liver Physiol 1981; 240: G 409–16.

7. Schmidt, B. Новое связывающее фосфат на основе лантана снижает абсорбцию фосфора в кишечнике у кошек/ Schmidt B., Delport P., Spiecker-Hauser U. // VetPharmacolTher 2006; 29 (дополнение 1): 206–7.

8. Antibacterial therapy in kidney pathology of small domestic animals / A. S. Chirkova, K. A. Sidorova, L. N. Skosyrskikh, M. V. Shchipakin // Regulatory and legal regulation in veterinary medicine. – 2024. – No. 1. – pp. 54-58. – DOI 10.52419/issn2782-6252.2024.1.54.